Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (14452)	12/3/2004 9:23:26 AM
From: rkrw	Read Replies (2) of 52153

Is a pivotal trial that measures cancer risk for intrinsa (or libigel) practical? Would a (theoretical) increased cancer risk for micro testosterone doses emerge in a one year study no matter how many patients? Wasn't the WHI tens of thousands of patients and 10 years? How many years until they saw signals? I'm sure the fda will be more reasonable, so it will be interesting to see what they agree to. BTW: Some interesting comments on (in)validity of WHI trial on NPR. Control group and placebo group not well matched. Lots of interest in a redo. Panel comments on 1 excess "encounter" being weak could favor bpa if their plus three trysts holds up. Maybe those frigid republican abstinence mongers would agree +3 is a nice thing :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next